Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation
© Ahmad et al.; licensee BioMed Central Ltd. 2012
Received: 14 September 2012
Accepted: 26 November 2012
Published: 28 November 2012
Expression profile of the toll like receptors (TLRs) on PBMCs is central to the regulation of proinflammatory markers. An imbalance in the TLRs expression may lead to several types of inflammatory disorders. Furthermore, the dynamic regulation of inflammatory activity and associated impaired production of cytokines by peripheral blood mononuclear cells (PBMCs) in obese individulas remain poorly understood. Therefore, we determined the perturbation in TLRs (TLR2 and TLR4), their adaptor proteins (MyD88, IRAK1 and TRAF6) expression in PBMCs/subcutaneous adipose tissue (AT) as well as inflammatory cytokines changes in obese individuals.
mRNA expression levels of TLR2, TLR4, IL-6, TNF-α and adaptor proteins were determined by RT-PCR. TLR2, TLR4 and adaptor proteins expression in AT was determined by immunohistochemistry.
Obese and overweight individuals showed significantly increased expression of TLR2, TLR4 and MyD88 in both PBMCs and AT as compared with lean individuals (P < 0.05). Interestingly, we found a remarkably higher expression of TLRs in obese and overweight individuals with type 2 diabetes (P < 0.05). Increased expression of TLR2, TLR4, MyD88 and IRAK1 correlated with body mass index (BMI) (TLR2: r = 0.91; TLR4: r = 0.88, P <0.0001; MyD88: r = 0.95, P < 0.0001; IRAK1 r = 0.78, P < 0.002). TLRs’ expression was also correlated with fasting blood glucose (FBG) (TLR2: r = 0.61, P < 0.002; TLR4: r = 0.52, P < 0.01) and glycated haemoglobin (HbA1c) ( TLR2: r = 0.44, P <0.03; TLR4: r = 0.48, P < 0.03). Transcript levels of IL-6 and TNF-α were highly elevated in obese subjects compared to lean subjects. There was a strong association of TLRs’ expression in PBMCs with TNF-α (TLR2: r = 0.92; TLR4: r = 0.92; P < 0.0001) and IL-6 (TLR2: r = 0.91, P < 0.0001; TLR4: r = 0.81; P < 0.001). Similarly adaptor proteins were significantly correlated with TNF-α (MyD88: r = 0.9, P < 0.0001; IRAK1: r = 0.86; P < 0.0002) and IL-6 (MyD88: r = 0.91, P < 0.0001; IRAK1: 0.77; P < 0.002).
TLRs and adapter proteins were overexpressed in PBMCs from obese subjects, which correlated with increased expression of TNF-α and IL-6. This association may explain a potential pathophysiological link between obesity and inflammation leading to insulin resistance.
Obesity is associated with a low-grade systemic chronic inflammation that is linked to insulin resistance, cardiovascular diseases and type-2 diabetes [1–3]. Obesity-induced inflammation is characterized by the abnormal production of pro- and anti-inflammatory adipocytokines. It has been found that resident macrophages in adipose tissue are mainly responsible for the production of inflammatory cytokines. The dynamic regulation of inflammatory activity and associated impaired production of cytokines/chemokines by PBMCs and adipocytes from obese individuals remain poorly understood. Changes in the expression profile of different receptors, ligands and adhesion molecules on PBMCs may lead to the development of different immunological diseases.
TLRs are transmembrane proteins involved in detection of microbes upon infection and play a crucial role in the host immune defence; 13 members of the TLR family in mammals (11 members in human) are known so far . Structurally, TLRs are characterized by an extracellular leucine-rich repeat (LRR) domain, a domain involved in the recognition of pathogen-associated molecular patterns (PAMPs) and a cytoplasmic Toll/IL-1 (TIR) domain that activates downstream signaling molecules including MyD88, IRAKs and TRAF6 . Activation of these adaptor proteins stimulates multiple cascades including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (MAPK) pathways and activation of NF-kB signaling and the resulting up-regulation of diverse inflammatory mediators, such as cytokines, chemokines, and adhesion molecules, which together, serve essential functions in promoting inflammation. Increased activity of TLR2 and TLR4 has been found in diabetic patients and is associated with the pathogenesis of diabetes and atherosclerosis in both clinical and experimental conditions [6–9]. TLR2 and TLR4 bind to components of the Gram-positive and -negative bacteria, respectively . In addition, ligands for TLR2 and TLR4 include free fatty acids, high-mobility group B1 protein (HMGB1), heat shock protein-60 (HSP60), heat shock protein-70 (HSP70), endotoxin, hyaluronan, advanced glycation end (AGE) products, and extracellular matrix components .
The role of TLR2 and TLR4 has been suggested in conventional insulin resistance (IR) target tissues like skeletal muscle and adipose tissue of Type 2 diabetes subjects [11, 12]. TLR4 was described as a molecular link between free fatty acids, inflammation, and the innate immune system . High TLR4 mRNA expression was reported in differentiating adipose tissue of db/db mice . Adipocytes produced IL-6 via TLR4 activation and the upregulation of osteopontin further exacerbated adipose tissue inflammation and insulin resistance . While these important observations from animal and human tissue data create an interest to see a role for TLR2 and TLR4 in obesity, it remains unknown whether alterations in TLR2 and TLR4 expression and associated inflammatory cytokines contribute to systemic inflammation which causes induction of insulin resistance in obese individuals. Therefore, we determined the changes in expression of TLRs in PBMCs/AT and associated inflammatory cytokines (TNF-α and IL-6) in obese individuals. We found elevated expression of TLRs and their adaptor proteins in PBMCs and AT. Elevated expression of TLRs and their adaptor proteins were significantly correlated with inflammatory cytokines. The localization of TLRs in adipose tissue was confirmed by immunohistochemistry. This study supports a model where the increased TLRs’ expression relates with the elevated cytokine expression in PBMCs from obese subjects.
Study Participants and clinical laboratory evaluation
Characteristics of the study participants
Age range (years)
Body mass index
23.19 ± 1.27
23.71 ± 0.97
28.23 ± 1.16
27.99 ± 0.71
34.71 ± 2.97
32.73 ± 2.45
Fasting blood glucose (mmol/l)
5.00 ± 0.77
9.40 ± 5.37
5.04 ± 0.47
9.46 ± 2.55
5.73 ± 0.95
9.70 ± 3.04
Glycosylated haemoglobin (%)
5.73 ± 0.98
9.85 ± 1.90
5.52 ± 0.56
9.35 ± 2.73
5.84 ± 0.65
8.12 ± 1.61
4.85 ± 0.94
4.70 ± 15
4.80 ± 0.73
4.61 ± 0.57
5.33 ± 1.06
5.71 ± 0.90
HDL cholesterol (mmol/l)
1.27 ± 0.31
1.17 ± 0.41
1.18 ± 0.17
1.40 ± 0.47
1.13 ± 0.24
1.07 ± 0.13
LDL cholesterol (mmol/l)
3.05 ± 0.81
2.95 ± 1.48
3.10 ± 0.68
2.52 ± 0.22
3.80 ± 2.25
3.25 ± 0.70
1.12 ± 0.67
1.24 ± 0.95
1.14 ± 0.72
1.48 ± 0.99
1.97 ± 1.13
2.95 ± 1.12
Peripheral blood mononuclear cells (PBMCs)
For PBMCs isolation, fresh blood samples were collected from participants in EDTA-tubes. PBMCs were isolated by using Ficoll-Hypaque density gradient centrifugation .
Subcutaneous adipose tissue biopsy
Human adipose tissue samples were collected via abdominal subcutaneous fat pad biopsy lateral to the umbilicus using standard surgical techniques. In brief, the region was sterilized using alcohol, and locally anesthetized with 2 ml 2% lidocaine. Through a small superficial 0.5 cm skin incision, fat tissue was collected via punch biopsy. Tissue samples were stored in formalin or snap-frozen in liquid nitrogen and stored at −80°C. Samples were then used for immunohistochemical staining.
Frozen sections (4 μm) of adipose tissue were cut. Slides were deparaffinized in xylene and rehydrated in pure ethanol to water. Antigen retrieval was done by placing the slides in target retrieval solution pH6.0 (Dako) in the pressure cooker boiling for 8 minutes and cooling down for 15 minutes. After washing in phosphate buffer saline (PBS), endogenous peroxidase was blocked with 3% H2O2 for 30 minutes. The slides were blocked with 5% milk for 1 hour followed by the 1 hour incubation with 1%BSA solution. The slides were incubated in primary antibody overnight at room temperature in 1:300 dilution of rabbit polyclonal TLR-2 antibody (ProSci Incorporated), 1:400 dilution of rabbit polyclonal TLR-4 antibody (ProSci Incorporated), 1:200 dilutions of rabbit polyclonal antibody (ProSci Incorporated), 1:200 dilution of TRAF6 antibody (ProSci Incorporated), 1:200 dilution of MyD88 (ProSci Incorporated) and 1:200 dilution of IRAK antibody (ProSci Incorporated). After washing with PBS–0.05% Tween, slides were incubated for 1 hour with the respective secondary antibodies. Bound antibody was detected with HRP EnVision Plus Kit. Color was developed in 3, 3’-diaminobenzidine chromogen substrate. The sections were then washed in running tap water, lightly counterstained with Gill’s hematoxylin, dehydrated through ascending graded alcohols, cleared in xylene, and mounted in DPX. Two different observers who were blinded to the source of the tissues quantified the expression of each antigen semiquantitatively on a 3-point scale, where 0 = no staining; 1 = mild expression, limited areas stained; and 3 = strong expression, strong overall staining. Immunohistochemical staining of the section of human spleen tissue (HST) was used as positive control for TLR2. Immunohistochemical staining of the section of breast cancer tissue was used as positive control for TLR4 .
Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted using RNeasy kit (Qiagen). The cDNA was synthesized with 0.5ug of total RNA using high capacity cDNA reverse transcription kit (Invitrogen). Polymerase chain reaction (PCR) was performed using the One Step PCR kit (Promega). The primer pairs used were as follows: TLR2 Fwd (5′-ATTGTGCCCATTGCTCTTTC-3′) and TLR2 Rev (5′-TTCTTCCTTGGAGAGGCTGA −3′); TLR4 Fwd (5′-AATCCCCTGAGGCATTTAGG-3′) and TLR4 Rev (5′-CCCCATCTTCAATTGTCTGG −3′); MyD88 Fwd (5′-GGATGGTGGTGGTTGTCTCT-3′) and MyD88 Rev (5′-AGGATGCTGGGGAACTCTTT-3′); IRAK1 Fwd (5′- AGCCCCTTCTTCTACCAAGC-3′) and IRAK1 Rev (5′-AGGAAGCTCTGCTTCACTGC-3′) TRAF6 Fwd (5′-CTGCAAAGCCTGCATCATAA-3′) and TRAF6 Rev (5′- GGGGACAATCCATAAGAGCA −3′); TNF-α Fwd (5′-CAGAGGGCCTGTACCTCATC-3′) and TNF-α Rev (5′- GGAAGACCCCTCCCAGATAG −3′); IL-6 Fwd (5′- CAGGGGTGGTTATTGCATCT-3′) and IL-6 Rev (5′-AAAGAGGCACTGGCAGAAAA-3′) and GAPDH Fwd (5′-ATCGTGGAAGGACTCATGACCACA-3′) and GAPDH Rev 5′-TAGAGGCAGGGATGATGTTCTGGA-3′. The RNA was reverse-transcribed at 50°C for 30 minutes and reverse transcriptase was inactivated at 95°C for 15 minutes. PCR was run at: 30 cycles of 94°C for 1 minute, 50°C for 1 minute, 72°C for 1 minute, and a final extension step at 72°C for 10 minutes. The PCR product (10 μl) was analyzed on 1.4% agarose gel to detect TLR2, TLR4, MyD88, IRAK1, TRAF6, IL-6, TNF-α and GAPDH cDNA amplification. Relative band quantification was performed by using Gel Doc™ XR + imaging system (Bio Rad,USA). Density of the bands was expressed in arbitrary units. Jurkat cells were used as a –ve control for TLR2 and TLR4 . THP1 cells were used for + ve control for TLR2 and TLR4 .
Data were presented as mean ± standard deviation, unless otherwise indicated. Unpaired Student t test was used to compare means between groups. Correlation and linear regression were used to see the association between different variables. For all analyses, P value < 0.05 was considered significant. All statistical analysis was performed with GraphPad Prism software (La Jolla, CA, USA).
Elevated expression of TLRs in PBMCs from obese subjects
Elevated expression of adaptor proteins in PBMCs from obese subjects
TLRs and MyD88 are upregulated in subcutaneous adipose tissue from obese subjects
Increased expression of TNF- and IL-6 is correlated with TLRs expression in PBMCs of obese subjects
Expression of TLRs in PBMCs from obese subjects with type 2 diabetes
Increased TLRs expression is correlated with FBG and HbAIc
Correlation of TLRs with Fasting Blood Glucose and HbA1c
Fasting Blood Glucose (mmol/l)
Fasting Blood Glucose (mmol/l)
Obesity is associated with a low-grade systemic chronic inflammatory state characterized by abnormal production of pro- and anti-inflammatory adipocytokines leading to immune dysfunction and contributing to increased disease risk. Precise triggers for obesity-induced inflammation are not yet fully understood. Activation of PBMCs is an important initial step in the cascades of events leading to many inflammatory diseases including insulin resistance. Since expression of receptors on cells is a key element in the regulation of proinflammatory cytokines, we determined whether TLRs (TLR2 and TLR4) and inflammatory cytokines expression was simultaneously modulated on PBMCs in obesity.
Our data demonstrated alterations in TLR2 and TLR4 expressions in PBMCs and adipose tissues from obese subjects. In parallel, abnormalities in cytokines expression were found in PBMCs from obese individuals. Moreover, we found that there was a strong association between TLRs’ expression and cytokines (IL-6 and TNF-) measured simultaneously in PBMCs. Recent findings indicate that the TLRs which are up-regulated in the affected tissue of most inflammatory disorders can mediate crosstalk between the immune systems and body metabolism . Increased TLRs activity was reported in patients with metabolic syndrome . Elevated TLR2 and TLR4 expression was assessed in artherosclerotic lesions . Higher expression of TLRs 3 and 4 in other conditions, such as an early stage of RA suggests that modulation in TLR expression does result during inflammatory states . We found that markedly increased TLR2 and TLR4 levels in adipose tissue from obese subjects related with their increased expression on PBMCs. This could be the result of migration of inflammatory monocytes/macrophages from the peripheral compartment to the adipose tissue. Shi et al. (2006) argued that the increased expression of TLR4 mRNA in total adipose tissue extracts in two models of obesity could be due, in part, to increased numbers of macrophages known to reside in fat tissue of obese animals. Since a preferential macrophage infiltration into obese adipose tissue was demonstrated , it was suggested that the toll-like receptors’ expression in adipose tissue was mainly due to macrophages .
The enhanced expression of cytokines we observed in obese subjects could be explained by an elevated expression of TLRs on PBMCs. Other factors, such as increased free fatty acids, can influence TLRs responsiveness and explain the increased response observed in obese individuals. Saturated free fatty acids which are elevated in case of obesity are able to augment TLR induced cytokine production [29, 30]. This could be a reason, in part, that obese individuals are more prone to developing insulin resistance. There is a clear link between TLR activation and insulin resistance. Free fatty acids cause insulin resistance in TLRs dependent manner. Recently pro-inflammatory effects of resistin were seen through its activation of TLR4  and other endogenous ligands such as HMGB1 or hyaluronan fragments or HSPs also served as TLR4 or TLR2 activators . Mice lacking TLR2 are substantially protected from diet-induced adiposity, insulin resistance, hypercholesterolemia, and hepatic steatosis and TLR2 deletion was associated with attenuation of adipocyte hypertrophy as well as diminished macrophage infiltration and inflammatory cytokine expression . It was reported that the absence of TLR2 attenuated local inflammatory cytokine expression and related signaling and increased insulin action specifically in the liver . Notably, only a few studies so far have described the responsiveness of TLRs to free fatty acid in insulin resistance and cytokine production. Interestingly, TLR expression modulation on PBMCs and adipose tissues in obese individuals remains poorly defined. The present data show over-expression of TLR2 and TLR4 on both PBMCs and adipose tissues which may explain their increased response to endogenous TLR ligands. Our findings suggest that TLRs modulation is linked with expression of proinflammatory cytokines in obese individuals.
The prior data demonstrate a correlation between TLR2/4 expression and BMI in subjects with type 2 diabetes ; however, the exact mechanism by which these two clinical predictors are interlinked remains undefined. There is lacking information about the relation of TLRs modulation and BMI in obese individuals. Expression of TLR2 and TLR4 on PBMCs varied widely among the individuals with different BMI that we observed. The extent of the obesity-induced up-regulation of TLR2/TLR4 genes and related proinflammatory cytokines cascades related to the BMI values. We found that TLR2 and TLR4 and inflammatory cytokines were overexpressed in PBMCs from obese subjects and this TLRs/cytokines overexpression correlated with the BMI. Increased expression of TLRs was correlated with FBG and HbAIc. More importantly, our data show a remarkable difference in the level of expression of toll-like receptors between obese individuals with and without diabetes. Overall, these results suggest that the overexpression of TLR2 and TLR4 on both PBMCs and adipose tissues together with the enhanced production of proinflammatory cytokines may pave way for the development of insulin resistance in obese individuals, leading to type 2 diabetes.
In conclusion, we found that TLR2 and TLR4 were overexpressed on PBMCs/adipose tissues from obese subjects which correlated with the increased expression of proinflammatory cytokines. This association may explain a potential pathophysiological link between obesity and inflammation, to subsequently result in development of insulin resistance and type 2 diabetes.
This work was financially supported by the Kuwait Foundation for the Advancement of Sciences (KFAS). We acknowledge individuals who participated in the study. We also thank Mr. Azadali Moorji and Mr. Sriraman Devarajan for their technical assistance in storing the blood samples and biopsies.
- Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003, 144: 2195-2200.View ArticlePubMedGoogle Scholar
- Greenberg AS, Obin MS: Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006, 83: 461S-465S.PubMedGoogle Scholar
- Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest. 2006, 116: 1793-1801.PubMed CentralView ArticlePubMedGoogle Scholar
- Trudler D, Farfara D, Frenkel D: Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators Inflamm. 2010, 2010: 1-12.View ArticleGoogle Scholar
- Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511.View ArticlePubMedGoogle Scholar
- Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006, 116: 3015-3025.PubMed CentralView ArticlePubMedGoogle Scholar
- Wong FS, Wen L: Toll-like receptors and diabetes. Ann N Y Acad Sci. 2008, 1150: 123-132.View ArticlePubMedGoogle Scholar
- Curtiss LK, Tobias PS: Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res. 2009, 50 (Suppl): S340-S345.PubMed CentralPubMedGoogle Scholar
- Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I: Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008, 93: 578-583.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004, 76: 514-519.View ArticlePubMedGoogle Scholar
- Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N: Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes. 2008, 57: 2595-2602.PubMed CentralView ArticlePubMedGoogle Scholar
- Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007, 292: E740-E747.View ArticlePubMedGoogle Scholar
- Song MJ, Kim KH, Yoon JM, Kim JB: Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun. 2006, 346: 739-745.View ArticlePubMedGoogle Scholar
- Samuvel DJ, Sundararaj KP, Li Y, Lopes-Virella MF, Huang Y: Adipocyte-mononuclear cell interaction, Toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism. J Biol Chem. 2010, 285: 3916-3927.PubMed CentralView ArticlePubMedGoogle Scholar
- Ahmad A, Ahmad R, Toma E, Morisset R, Menezes J: Impaired induction of IL-15 in response to herpes simplex virus type 1 infection in peripheral blood mononuclear cells of HIV-infected patients. AIDS. 2000, 14: 744-746.View ArticlePubMedGoogle Scholar
- Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010, 10: 665-PubMed CentralView ArticlePubMedGoogle Scholar
- Ye Z, Gan YH: Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells. J Biol Chem. 2007, 282: 4479-4484.View ArticlePubMedGoogle Scholar
- Ahmad R, El Bassam S, Cordeiro P, Menezes J: Requirement of TLR2-mediated signaling for the induction of IL-15 gene expression in human monocytic cells by HSV-1. Blood. 2008, 112: 2360-2368.View ArticlePubMedGoogle Scholar
- Borst SE: The role of TNF-alpha in insulin resistance. Endocrine. 2004, 23: 177-182.View ArticlePubMedGoogle Scholar
- Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999, 107: 119-125.View ArticlePubMedGoogle Scholar
- Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002, 51: 3391-3399.View ArticlePubMedGoogle Scholar
- Klover PJ, Zimmers TA, Koniaris LG, Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003, 52: 2784-2789.View ArticlePubMedGoogle Scholar
- Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376.View ArticlePubMedGoogle Scholar
- Jialal I, Huet BA, Kaur H, Chien A, Devaraj S: Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care. 2012, 35: 900-904.PubMed CentralView ArticlePubMedGoogle Scholar
- Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002, 105: 1158-1161.PubMedGoogle Scholar
- Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D: Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008, 58: 3684-3692.View ArticlePubMedGoogle Scholar
- Harman-Boehm I, Bluher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, Shai I, Kloting N, Stumvoll M, Bashan N, Rudich A: Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab. 2007, 92: 2240-2247.View ArticlePubMedGoogle Scholar
- Poulain-Godefroy O, Le Bacquer O, Plancq P, Lecoeur C, Pattou F, Fruhbeck G, Froguel P: Inflammatory role of Toll-like receptors in human and murine adipose tissue. Mediators Inflamm. 2010, 2010: 823486-PubMed CentralView ArticlePubMedGoogle Scholar
- Opie LH, Walfish PG: Plasma free fatty acid concentrations in obesity. N Engl J Med. 1963, 268: 757-760.View ArticlePubMedGoogle Scholar
- Dasu MR, Devaraj S, Park S, Jialal I: Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010, 33: 861-868.PubMed CentralView ArticlePubMedGoogle Scholar
- Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI: Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010, 14: 1419-1431.PubMed CentralView ArticlePubMedGoogle Scholar
- Wagner H: Endogenous TLR ligands and autoimmunity. Adv Immunol. 2006, 91: 159-173.View ArticlePubMedGoogle Scholar
- Himes RW, Smith CW: Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 2010, 24: 731-739.PubMed CentralView ArticlePubMedGoogle Scholar
- Kuo LH, Tsai PJ, Jiang MJ, Chuang YL, Yu L, Lai KT, Tsai YS: Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse. Diabetologia. 2011, 54: 168-179.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.